160 related articles for article (PubMed ID: 23956082)
1. [Expression and regulation of the SOST gene].
Qin LJ; Ding DX; Cui LL; Huang QY
Yi Chuan; 2013 Aug; 35(8):939-47. PubMed ID: 23956082
[TBL] [Abstract][Full Text] [Related]
2. Methylation of bone
Shan Y; Wang L; Li G; Shen G; Zhang P; Xu Y
Biochem Cell Biol; 2019 Aug; 97(4):369-374. PubMed ID: 30257098
[TBL] [Abstract][Full Text] [Related]
3. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
4. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
5. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway.
Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ
Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
8. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
[TBL] [Abstract][Full Text] [Related]
9. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
10. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
11. Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2.
Fujiwara M; Kubota T; Wang W; Ohata Y; Miura K; Kitaoka T; Okuzaki D; Namba N; Michigami T; Kitabatake Y; Ozono K
Bone; 2016 Apr; 85():91-8. PubMed ID: 26851122
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
Delgado-Calle J; Sañudo C; Bolado A; Fernández AF; Arozamena J; Pascual-Carra MA; Rodriguez-Rey JC; Fraga MF; Bonewald L; Riancho JA
J Bone Miner Res; 2012 Apr; 27(4):926-37. PubMed ID: 22162201
[TBL] [Abstract][Full Text] [Related]
13. Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis.
Ye W; Wang Y; Mei B; Hou S; Liu X; Wu G; Qin L; Zhao K; Huang Q
Bone; 2018 Mar; 108():132-144. PubMed ID: 29307778
[TBL] [Abstract][Full Text] [Related]
14. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.
Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M
Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980
[TBL] [Abstract][Full Text] [Related]
15. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
16. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
17. Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone.
Pérez-Campo FM; Santurtún A; García-Ibarbia C; Pascual MA; Valero C; Garcés C; Sañudo C; Zarrabeitia MT; Riancho JA
Calcif Tissue Int; 2016 Sep; 99(3):302-9. PubMed ID: 27154028
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of GSK3β Stimulates BMP Signaling and Decreases SOST Expression Which Results in Enhanced Osteoblast Differentiation.
Schoeman MA; Moester MJ; Oostlander AE; Kaijzel EL; Valstar ER; Nelissen RG; Löwik CW; de Rooij KE
J Cell Biochem; 2015 Dec; 116(12):2938-46. PubMed ID: 26095393
[TBL] [Abstract][Full Text] [Related]
19. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
20. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
